Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
Aged
Aged, 80 and over
Animals
Antigens, CD34
/ immunology
Apoptosis
Case-Control Studies
Cell Proliferation
Female
Humans
Leukemia, Myeloid, Acute
/ etiology
Leukemia, Myelomonocytic, Chronic
/ complications
Male
Mice
Mice, Inbred NOD
Mice, SCID
Middle Aged
Neoplastic Stem Cells
/ drug effects
Phenotype
Prognosis
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
13
11
2020
accepted:
11
03
2021
revised:
04
02
2021
pubmed:
1
4
2021
medline:
31
12
2021
entrez:
31
3
2021
Statut:
ppublish
Résumé
Chronic myelomonocytic leukemia (CMML) is a stem cell-derived neoplasm characterized by dysplasia, uncontrolled expansion of monocytes, and substantial risk to transform to secondary acute myeloid leukemia (sAML). So far, little is known about CMML-initiating cells. We found that leukemic stem cells (LSC) in CMML reside in a CD34
Identifiants
pubmed: 33785864
doi: 10.1038/s41375-021-01227-z
pii: 10.1038/s41375-021-01227-z
pmc: PMC7611912
mid: EMS119146
doi:
Substances chimiques
Antigens, CD34
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3176-3187Subventions
Organisme : Austrian Science Fund FWF
ID : F 4704
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : P 30625
Pays : Austria
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4:766–70.
pubmed: 2232890
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.
pubmed: 6952920
doi: 10.1111/j.1365-2141.1982.tb08475.x
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British cooperative leukaemia group. Br J Haematol. 1994;87:746–54.
pubmed: 7986717
doi: 10.1111/j.1365-2141.1994.tb06734.x
Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014;165:273–86.
pubmed: 24467717
doi: 10.1111/bjh.12756
McCullough KB, Patnaik MM. Chronic myelomonocytic leukemia: a genetic and clinical Update. Curr Hematol Malig Rep. 2015;10:292–302.
pubmed: 26122388
doi: 10.1007/s11899-015-0271-4
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Beau MML, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
pubmed: 27069254
doi: 10.1182/blood-2016-03-643544
Orazi A, Bennett JM, Germing U, Brunning RD, Bain BJ, Cazzola M et al. Chronic myelomonocytic leukaemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, 2017, pp 82–86.
Kohlmann A, Grossmann V, Klein H-U, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858–65.
pubmed: 20644105
doi: 10.1200/JCO.2009.27.1361
Itzykson R, Duchmann M, Lucas N, Solary E. CMML: clinical and molecular aspects. Int J Hematol. 2017;105:711–9.
pubmed: 28455647
doi: 10.1007/s12185-017-2243-z
Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95:97–115.
pubmed: 31736132
doi: 10.1002/ajh.25684
Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62:798–801.
pubmed: 19734476
doi: 10.1136/jcp.2009.065904
Gur HD, Loghavi S, Garcia-Manero G, Routbort M, Kanagal-Shamanna R, Quesada A, et al. Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations. Am J Surg Pathol. 2018;42:799–806.
pubmed: 29596070
doi: 10.1097/PAS.0000000000001058
Sperr WR, Horny H-P, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002;127:140–2.
pubmed: 11919425
doi: 10.1159/000048186
Sotlar K, Fridrich C, Mall A, Jaussi R, Bültmann B, Valent P, et al. Detection of c-kit point mutation Asp-816 –> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res. 2002;26:979–84.
pubmed: 12363464
doi: 10.1016/S0145-2126(02)00041-3
Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019;104:1935–49.
pubmed: 31048353
pmcid: 6886439
doi: 10.3324/haematol.2019.222059
Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, et al. A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia. 2018;32:1850–6.
pubmed: 29712989
doi: 10.1038/s41375-018-0121-1
Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428–36.
doi: 10.1200/JCO.2012.47.3314
pubmed: 23690417
Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408–17.
pubmed: 27385790
pmcid: 5036538
doi: 10.1182/blood-2016-05-714030
Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, et al. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget. 2016;7:57021–35.
pubmed: 27486981
pmcid: 5302970
doi: 10.18632/oncotarget.10937
Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, et al. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European hematology association and the European leukemiaNet. Hemasphere. 2018;2:e150.
pubmed: 31723789
pmcid: 6745959
doi: 10.1097/HS9.0000000000000150
Kröger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the european group for blood and marrow transplantation (EBMT). Br J Haematol. 2002;118:67–73.
pubmed: 12100129
doi: 10.1046/j.1365-2141.2002.03552.x
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62.
pubmed: 28096091
pmcid: 5524528
doi: 10.1182/blood-2016-06-724500
Dick JE, Lapidot T, Pflumio F. Transplantation of normal and leukemic human bone marrow into immune-deficient mice: development of animal models for human hematopoiesis. Immunol Rev. 1991;124:25–43.
pubmed: 1804779
doi: 10.1111/j.1600-065X.1991.tb00614.x
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.
pubmed: 7509044
doi: 10.1038/367645a0
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–7.
pubmed: 9212098
doi: 10.1038/nm0797-730
Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia. 2005;19:435–41.
pubmed: 15674418
doi: 10.1038/sj.leu.2403649
Kavalerchik E, Goff D, Jamieson CHM. Chronic myeloid leukemia stem cells. J Clin Oncol. 2008;26:2911–5.
pubmed: 18539972
doi: 10.1200/JCO.2008.17.5745
Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med. 2007;13:470–81.
pubmed: 17981087
pmcid: 4344828
doi: 10.1016/j.molmed.2007.09.003
Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 2009;23:25–42.
pubmed: 18800146
doi: 10.1038/leu.2008.246
Copland M. Chronic myelogenous leukemia stem cells: what’s new? Curr Hematol Malig Rep. 2009;4:66–73.
pubmed: 20425417
doi: 10.1007/s11899-009-0010-9
Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2011;11:56–71.
pubmed: 21062243
doi: 10.2174/156800911793743655
Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008;112:568–75.
pubmed: 18523148
doi: 10.1182/blood-2007-10-118331
Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–67.
pubmed: 15306667
doi: 10.1056/NEJMoa040258
Järås M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010;107:16280–5.
pubmed: 20805474
pmcid: 2941341
doi: 10.1073/pnas.1004408107
Herrmann H, Sadovnik I, Cerny-Reiterer S, Rülicke T, Stefanzl G, Willmann M, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123:3951–62.
pubmed: 24778155
doi: 10.1182/blood-2013-10-536078
Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2:17ra9–17ra9.
pubmed: 20371479
pmcid: 3005290
doi: 10.1126/scitranslmed.3000349
Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104:11008–13.
pubmed: 17576927
pmcid: 1904175
doi: 10.1073/pnas.0704271104
van Rhenen A, van Dongen GAMS, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659–66.
pubmed: 17609428
doi: 10.1182/blood-2007-03-083048
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–99.
pubmed: 19632179
pmcid: 2726837
doi: 10.1016/j.cell.2009.05.045
Zhang Y, He L, Selimoglu-Buet D, Jego C, Morabito M, Willekens C, et al. Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. Blood Adv. 2017;1:972–9.
pubmed: 29296739
pmcid: 5737594
doi: 10.1182/bloodadvances.2017004903
Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, et al. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017;130:397–407.
pubmed: 28576879
pmcid: 5533204
doi: 10.1182/blood-2017-01-763219
Ramshaw HS, Bardy PG, Lee MA, Lopez AF. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol. 2002;30:1124–31.
pubmed: 12384142
doi: 10.1016/S0301-472X(02)00903-7
Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32:364–72.
pubmed: 24633240
pmcid: 4017589
doi: 10.1038/nbt.2858
Valent P, Schmidt G, Besemer J, Mayer P, Zenke G, Liehl E, et al. Interleukin-3 is a differentiation factor for human basophils. Blood. 1989;73:1763–9.
pubmed: 2469498
doi: 10.1182/blood.V73.7.1763.1763
Saito H, Hatake K, Dvorak AM, Leiferman KM, Donnenberg AD, Arai N, et al. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. PNAS. 1988;85:2288–92.
pubmed: 3258425
pmcid: 279976
doi: 10.1073/pnas.85.7.2288
Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, et al. Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML. Clin Cancer Res. 2016;22:2051–61.
pubmed: 26607600
doi: 10.1158/1078-0432.CCR-15-0767
Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, et al. STAT5 is expressed in CD34
pmcid: 7225958
doi: 10.3390/cancers12041021
Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018;32:1713–26.
pubmed: 29728695
pmcid: 6087715
doi: 10.1038/s41375-018-0117-x
Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018;32:1135–46.
pubmed: 29472718
pmcid: 5940656
doi: 10.1038/s41375-017-0005-9
Müller‐Thomas C, Heider M, Piontek G, Schlensog M, Bassermann F, Kirchner T, et al. Prognostic value of indoleamine 2,3 dioxygenase in patients with higher‐risk myelodysplastic syndromes treated with azacytidine. Br J Haematol. 2020;190:361–70.
pubmed: 32350858
doi: 10.1111/bjh.16652
Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, et al. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Adv. 2020;4:5425–30.
pubmed: 33152058
pmcid: 7656937
doi: 10.1182/bloodadvances.2020002415
Lou Y, Shao L, Mao L, Lu Y, Ma Y, Fan C, et al. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: a multicenter retrospective study. Leuk Res. 2020;91:106317.
pubmed: 32092584
doi: 10.1016/j.leukres.2020.106317